The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients-Reference-Cited by-同舟云学术

The feasibility of withdrawing canakinumab in paediatric colchicine-resistant familial Mediterranean fever patients

Published:2021-10-06 Issue:5 Volume:39 Page:118-123
ISSN:1593-098X
Container-title:Clinical and Experimental Rheumatology
language:en
Short-container-title:

Author:

Sözeri Betül¹,Sönmez Hafize E.²,Karadağ Şerife G.³,Bağlan Esra⁴,Öztürk Kübra⁵,Çakan Mustafa⁶,Demir Ferhat⁷,Otar Yener Gülçin⁸,Özdel Semanur⁴,Aktay Ayaz Nuray⁹

Affiliation:

1. University of Health Science, Ümraniye Research and Training Hospital, Department of Paediatric Rheumatology, Istanbul, Turkey. drbetulsozeri@gmail.com

2. Kocaeli University, Department of Paediatric Rheumatology, Kocaeli, Turkey.

3. Sadi Konuk Research and Training Hospital, Department of Paediatric Rheumatology, Istanbul, Turkey.

4. Sami Ulus Research and Training Hospital, Department of Paediatric Rheumatology, Ankara, Turkey.

5. Istanbul Medeniyet University, Göztepe Research and Training Hospital, Department of Paediatric Rheumatology, Istanbul, Turkey.

6. University of Health Science, Zeynep Kamil Maternity and Children’s Diseases Research and Training Hospital, Department of Paediatric Rheumatology, Istanbul, Turkey.

7. University of Health Science, Ümraniye Research and Training Hospital, Department of Paediatric Rheumatology, Istanbul, Turkey.

8. Şanlıurfa Research and Training Hospital, Department of Paediatric Rheumatology, Şanlıurfa, Turkey.

9. Istanbul University, Faculty of Medicine, Department of Paediatric Rheumatology, Istanbul, Turkey.

Publisher

Clinical and Experimental Rheumatology

Subject

Immunology,Immunology and Allergy,Rheumatology

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database;Arthritis Research & Therapy;2024-04-08

2. A grey zone in canakinumab tapering: dose reduction or interval prolongation?;Rheumatology;2024-01-30

3. Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience;Pediatric Rheumatology;2023-11-23

4. The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study;Expert Opinion on Biological Therapy;2023-11-17

5. A score for predicting colchicine resistance at the time of diagnosis in familial Mediterranean fever: data from the TURPAID registry;Rheumatology;2023-05-25